ASCO 2017: Adjuvant Therapy in Melanoma: Current and Future

Speaker: Philippa Corrie

Philippa Corrie reports on 3 studies discussing various aspects of adjuvant therapy in melanoma. She presents first the safety results of 2 doses of ipilimumab, second if there is a role for bevacizumab in the adjuvant setting and third, a trial taking forward the question of adjuvant therapy in uveal melanoma.

Philippa Corrie reports on 3 studies discussing various aspects of adjuvant therapy in melanoma. She presents first the safety results of 2 doses of ipilimumab, second if there is a role for bevacizumab in the adjuvant setting and third, a trial taking forward the question of adjuvant therapy in uveal melanoma.

Abstracts as referenced in the ASCO 2017 programme

  • 9500: A phase III randomized study of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon alfa-2b for resected high-risk melanoma (U.S. Intergroup E1609): Preliminary safety and efficacy of the ipilimumab arms.
  • 9501: Adjuvant bevacizumab as treatment for melanoma patients at high risk of recurrence: Final results for the AVAST-M trial.
  • 9502: A randomized multicenter phase 3 trial of adjuvant fotemustine versus surveillance in high risk uveal melanoma (UM) patients (FOTEADJ).